{"filings":[{"id":95195,"accession_number":"0001493152-26-018220","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["1.01","2.03","3.03","5.02","8.01","9.01"],"status":"ready","headline":"Celularity closes $13.3M NexGel asset sale; Helena default notice on $1.97M note","event_type":"other_material","confidence":"high","bullets":["Closed asset sale to NexGel for $13.3M ($8.3M cash + $5M note), retired ~$13M debt.","Eligible for up to $20M milestones and royalties on net sales.","Helena exchanged for $1.97M note at 18%; default notice for late 10-K; potential 115% acceleration.","Co. terminated John Haines (SVP/CAO) and Stephen Brigido resigned (President, Degenerative)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108069,"accession_number":"0001493152-26-009471","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celularity licenses biomaterials portfolio for up to $35M; retains manufacturing, cuts costs","event_type":"other_material","confidence":"high","bullets":["Up to $35M cash: $15M upfront plus $20M milestone payments based on net sales targets.","Celularity will act as exclusive manufacturer of licensed products at its New Jersey FDA-compliant facility.","Workforce reduction and organizational realignment expected to lower operating costs and sharpen focus on longevity therapeutics.","Transaction expected to close no later than April 15, 2026, subject to customary conditions including financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108068,"accession_number":"0001493152-26-009017","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Celularity CFO Joseph DosSantos departs; John Sprague named acting CFO","event_type":"leadership","confidence":"high","bullets":["Joseph DosSantos left as SVP Finance and Acting CFO on Feb 27, 2026 for personal reasons.","John Sprague appointed Acting CFO effective same date.","No additional details on compensation or transition timeline provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108067,"accession_number":"0001493152-26-003100","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Celularity amends SVP Haines' agreement; severance doubled, COBRA extended, equity accelerated","event_type":"other_material","confidence":"high","bullets":["Comp Committee approved amendment to John Haines' employment agreement on Jan 16, 2026.","Severance period increased from 12 to 24 months upon qualifying termination.","COBRA payment extended to 18 months from prior term.","Equity options that would vest over 24 months post-termination will vest immediately upon termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124493,"accession_number":"0001493152-25-029033","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Celularity closes $10M financing with Philip A. Barach; issues senior secured and convertible notes","event_type":"debt","confidence":"high","bullets":["Gross proceeds at closing: $10.0M; potential additional $2.0M subject to conditions.","Senior secured term loan: $7.0M principal, 4% interest (12% on default), matures April 30, 2026 or upon qualified financing.","Secured convertible notes: up to $5.0M, 8% PIK interest, convertible at $1.66/share, maturity Dec 31, 2026.","Issued warrants to purchase 3,707,657 shares at $2.00/share, exercisable from June 19, 2026 to Dec 19, 2030.","Investor granted board observer rights; notes secured by first-priority liens on substantially all assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124492,"accession_number":"0001493152-25-028560","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Celularity annual meeting: directors elected despite majority withheld; equity plan increase fails","event_type":"other_material","confidence":"high","bullets":["Class I directors Peter Diamandis, Diane Parks, Geoffrey Ling elected; each received >4.5M votes for but >9.5M withheld.","Ratification of EisnerAmper LLP as auditor passed: 10,050,276 for, 31,337 against, 9,374,540 abstentions.","Proposal to increase 2021 Equity Incentive Plan by 3.5M shares failed: 4,342,023 for, 890,138 against, 9,368,069 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124491,"accession_number":"0001493152-25-026383","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Celularity receives FDA warning letter over Interfyl marketing claims","event_type":"regulatory","confidence":"high","bullets":["FDA warning letter received Dec 1, 2025, regarding marketing material for Interfyl (human connective tissue matrix).","Letter cites outcome-based and metabolic activity claims; company must limit such claims per Section 361 of CFR 1271.10.","No restriction on manufacturing, product shipment, recall, or ability to seek 510(k) clearance.","Company states no material impact on operational/financial expectations; resolution timeline uncertain.","Additional regulatory action may occur if issues not resolved to FDA's satisfaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124490,"accession_number":"0001493152-25-019839","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Celularity raises $2M initial tranche in $6.67M private placement of Series A Preferred and warrants","event_type":"other_material","confidence":"high","bullets":["Series A Preferred shares sold at 90% of stated value; $2M initial tranche closed Oct 24, 2025.","Up to three tranches totaling $6.67M stated value; warrants exercisable at $3.00/share for 25% of purchase price.","Conversion price lower of 110% of prior close or 95% of 7-day VWAP, floor $1.60; 5% dividend (18% on trigger event).","Proceeds used for working capital; investor capped at 4.99% beneficial ownership unless waived.","Shares issued exempt under Section 4(a)(2) and Regulation D; resale registration required within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141165,"accession_number":"0001641172-25-026245","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq confirms Celularity compliant with listing rule after late 10-Qs; deficiency closed","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Celularity on Sept 2, 2025 that it has regained compliance with Listing Rule 5250(c)(1).","Compliance determination based on the Aug 29, 2025 filing of Q1 2025 10-Q and Q2 2025 10-Q.","Listing Rule 5250(c)(1) requires timely filing of periodic financial reports.","The previously reported deficiency is now closed, removing immediate delisting risk.","Celularity is now current with its SEC periodic filings through June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141164,"accession_number":"0001641172-25-024623","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celularity retires all $41.6M senior secured debt via IP sale and license-back deal","event_type":"other_material","confidence":"high","bullets":["Retired all $32M principal plus $9.6M accrued interest on senior secured loans for total $41.6M.","Sold IP assets to Celeniv for $33,812,230; licensed back exclusively with five-year repurchase option.","Created four operating subsidiaries for advanced biomaterials, longevity cell therapy, biobanking, and CDMO.","Proceeds used to retire $27M RWI loan and $6,812,230 promissory note; prior note proceeds retired C.V. Starr loan.","Retained exclusive use of IP; balance sheet improved with removal of general security interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141163,"accession_number":"0001641172-25-023231","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celularity invests $2.9M in Defeye preferred stock; gets Nasdaq extension to Aug 31 for late filings","event_type":"other_material","confidence":"high","bullets":["Acquired 7,198.6 shares of Defeye Series Seed-2 Preferred Stock for $2.89M in product purchase credits.","Received Nasdaq notice of non-compliance for late Q1 2025 10-Q filing; submitted compliance plan.","Nasdaq extended deadline to Aug 31, 2025 to file both Q1 and Q2 10-Qs; risk of delisting if missed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141162,"accession_number":"0001641172-25-021831","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Celularity issues $6.81M promissory note and warrant to investor Lim Kok Thay","event_type":"debt","confidence":"high","bullets":["Issued $6,812,230 promissory note to Lim Kok Thay, 2% interest, matures March 21, 2026, secured by all company assets.","Issued warrant to purchase 3,700,000 shares of Class A common stock at $2.528/share, exercisable for 5 years.","Proceeds partly used to repay principal and accrued interest on C.V. Starr & Co. loan from March 2023.","The note and warrant were issued in unregistered transactions under exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141161,"accession_number":"0001641172-25-021556","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Celularity raises $2M via private placement of 1.23M shares and warrants","event_type":"other_material","confidence":"high","bullets":["Issued 1,230,769 shares of common stock and warrants to purchase 1,230,769 shares at $1.625 per unit.","Gross proceeds of $2M; net proceeds for working capital and general corporate purposes.","Warrants exercisable at $1.50 per share for two years from issuance date.","Private placement to an institutional investor; securities unregistered under Section 4(a)(2) and Regulation D.","Closing occurred on July 14, 2025; customary representations and warranties included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141159,"accession_number":"0001641172-25-021378","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K/A","filed_at":"2025-07-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Celularity reprices warrants for Starr and RWI, issues new warrants under forbearance amendments","event_type":"other_material","confidence":"high","bullets":["Repriced Starr warrants to $1.692/share; issued new warrant for 100,000 shares.","Repriced RWI warrants to $2.844/share; issued new warrant for 500,000 shares.","Warrant amendments and issuances executed under February 2025 binding term sheets.","Filed amended warrants for prior issuances dating from March 2023 to March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141160,"accession_number":"0001641172-25-020580","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Celularity raises $1.035M in private placement of 739,286 shares at $1.40/share","event_type":"other_material","confidence":"high","bullets":["Issue and sale of 739,286 shares of Class A common stock at $1.40 per share for gross proceeds of $1,035,000.","Warrant adjustment: exercise price of 1,311,093 warrants revised to $2.50 and expiration extended to June 30, 2030.","Closing expected during week of July 21, 2025; net proceeds to be used for working capital and general corporate purposes.","Securities offered in a private placement under Section 4(a)(2) and/or Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158967,"accession_number":"0001641172-25-014525","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Celularity terminates CFO Beers without cause; names DosSantos interim CFO","event_type":"leadership","confidence":"high","bullets":["CFO David Beers terminated without cause effective June 10, 2025; severance subject to release.","Termination not related to financial/operating results or reporting disagreements.","Joseph DosSantos (SVP Finance) appointed interim CFO; no additional compensation.","Company retained CFO Squad for outsourced accounting, SEC reporting, and consulting support.","Search for a permanent CFO is underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158966,"accession_number":"0001641172-25-014073","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Celularity appoints Vincent LeVien as Class II director, effective June 5, 2025","event_type":"leadership","confidence":"high","bullets":["Vincent LeVien appointed to Board as Class II director, serving until 2026 Annual Meeting.","Appointed to Audit Committee and Nominating & Corporate Governance Committee.","LeVien is Chairman and CEO of I Got a Guy, Inc., a network consulting firm.","No material arrangements or related-party transactions with the new director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158965,"accession_number":"0001641172-25-011751","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Celularity extends convertible note maturity to Aug 15, 2025; issues 100K shares","event_type":"debt","confidence":"medium","bullets":["Maturity of Convertible Promissory Note (dated March 13, 2024) extended from May 12, 2025 to August 15, 2025.","Issued 100,000 restricted common shares to YA II PN, Ltd. as consideration for the extension.","The shares carry piggyback registration rights for inclusion in future registration statements.","No principal amount or conversion rate of the note was disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158964,"accession_number":"0001641172-25-011253","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Dean Kehler resigns from Celularity board effective May 14, 2025","event_type":"leadership","confidence":"high","bullets":["Dean Kehler resigned as a director of Celularity Inc. on May 14, 2025.","The resignation was not related to any disagreement with the company.","No replacement director has been announced or appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}